St. Jude Medical (STJ) Announces ILUMIEN III Trial Met Primary Endpoint

Short resume:

ilumien
90%
statements
80%
angiography
80%
wire
70%
St. Jude Medical (STJ) Announces ILUMIEN III Trial Met Primary Endpoint

St. Jude Medical, Inc. (NYSE: STJ) announced the ILUMIEN III trial met its primary endpoint demonstrating percutaneous coronary intervention (PCI) guided by optical coherence tomography (OCT) to be superior to angiography in stent expansion and …
Source StreetInsider.com
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*